Post by
MikeyH on Jan 25, 2021 10:27am
Another slow bleed week ahead!
Hello all, hope you had a good weekend. Looks like more of the same this week... a continued slow bleed.
I think SONA has one last chance; they need some decent sales figures in a well-written NR, and soon. If they manage that in the next couple of weeks, there is still hope.
The alternative is, unfortunately, the end. Many here and on CEO.ca insist SONA is not just a one trick pony, but this is completely untrue. SONA is the dictionary definition of one. The GNR technology is many decades old, and unlikely to be commercialized for anything other than the COVID test. Being CTAB-free is only valuable for in-vivo applications, of which there are none for GNRs. Good luck to all
Comment by
MetalsDude on Jan 25, 2021 10:50am
If Sona doesn't have any sales contracts in Europe coming up and I'm guessing they don't they should take a page out of THRMs playbook and announce their saliva test achieved 85% accuracy and this will move SP up and then wait a month and then release another NR saying their Saliva test reached 90% accuracy which will drive SP again :)
Comment by
MikeyH on Jan 25, 2021 10:57am
I don't know if that will fool investors again. It worked last summer with the MRI 'validation' (which turned out to be nothing but a lab LoD), but surely people would realize they were trying the same trick again? But you are correct; they need to do something